Call for application: AI for antibody design 

German independent research institute BioMed X has announced the launch of a global call for application to identify biomedical scientists and inventors to form a new startup at AION Labs’, Israel. The company spearheads the adoption of AI technologies and computational science to solve therapeutic challenges. 

The chosen AION Labs startup team will be sponsored by several industry partners and supported by the Israel Innovation Authority (IIA). The sponsors of this call for application are AstraZeneca, Merck, Pfizer, Teva and the Israel Biotech Fund, with close support from Amazon Web Services (AWS). 

“We are excited to extend our portfolio of career opportunities for talented academic researchers to Israel,” said Dr Christian Tidona, Founder and Managing Director of the BioMed X Institute. “Located in the heart of the ’startup nation,’ AION Labs is the perfect place for biomedical scientists from around the globe to learn how to become successful biotech entrepreneurs.” 

Therapeutic antibodies are well established life-saving drugs. Discovery of existing therapeutic antibodies relies on immunisation or in-vitro selection from large, pre-defined libraries with limited sequence space coverage. Selecting a drug candidate from billions of potential antibody sequences is laborious and expensive and, in many cases, fails to identify functional antibodies. Recent advances in protein structure prediction, artificial intelligence (AI) algorithms, and increased availability of experimentally determined antigen-antibody structures present a unique opportunity for AI-driven antibody discovery. 

AION Labs is inviting computational biologists and biomedical scientists at academic and industry research labs worldwide to propose the development of a next-generation general computational platform for the design of high-affinity and biophysically well-behaved antibody binders directed towards epitopes of choice, starting from an antigen structure or antigen sequence as an input. The AION Labs pharma partners involved in this project will provide data for model training and their expertise in setting specifications and evaluating the outcome.  

“AION Labs is proud and excited to be launching our first call for application,” said Mati Gill, CEO of AION Labs. “We look forward to providing the chosen startup with our strong resources and mentorship as we work together to develop a cutting-edge solution to overcome the pharmaceutical challenge of selecting drug candidates from antibody sequences. This is just the beginning.” 

Find more on the application details at

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free